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Background: Statins are a major group of drugs that reduces LDL-C levels, which are proven
to have other beneficial effects such as preventing coronary events. The objective of this
study was to evaluate oxidative stress and select novel coronary artery disease risk factors
among coronary artery disease patients on statins.
Methods: In this observational, cross-sectional study, we compared total cholesterol, tri-
glycerides, HDL-cholesterol, LDL-cholesterol, apolipoprotein B, lipoprotein (a), homocys-
teine, reduced glutathione, glutathione peroxidase, superoxide dismutase, ascorbic acid,
malondialdehyde and oxidized LDL among male coronary artery disease patients on statin
therapy (group 2, n ¼ 151) with sex-matched, diabetic patients (group 3, n ¼ 80) as well as
healthy controls (group 1, n ¼ 84).
Results: Total cholesterol, triglycerides, HDL-cholesterol and LDL-cholesterol were signifi-
cantly lower among subjects of group 2 compared to other two groups. The novel risk
factors studied did not differ significantly between groups, except for a higher homocys-
teine level among group 2 subjects compared to the other two groups. Elevated oxidative
stress, indicated by lower reduced glutathione, glutathione peroxidase, and ascorbic acid
as well as higher malondialdehyde and oxidized LDL was observed among group 2 subjects.
Triglycerides, HDL-cholesterol, ascorbic acid and malondialdehyde were found to be in-
dependent predictors for coronary artery disease among this study population.
Conclusions: Though coronary artery disease subjects had healthy lipid profile, oxidative
stress, a recognized risk factor for coronary events, was still elevated among this patient
group. Novel risk factors were not found to be major predictors for coronary artery disease
among the study subjects.
Copyright © 2015, Cardiological Society of India. All rights reserved.hemistry, Amrita School of Medicine, Kochi 682041, Kerala, India. Tel.: þ91 9600123863.
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National Cholesterol Education Program Adult Panel III
guidelines identify the reduction of low density-lipoprotein
cholesterol [LDL-C] as the primary target of therapy for coro-
nary artery disease [CAD] patients.1 Statins are a major group
of drugs that reduces LDL-C levels by inhibiting HMG-CoA
reductase, the rate limiting enzyme involved in the hepatic
synthesis of cholesterol. Since the observed advantage of
statin therapy in reducing adverse cardiovascular events is
larger than that expected on the basis of lipid lowering alone,
statins are attributed to have cholesterol-independent bene-
ficial effects also.
Though LDL-C remains an important therapeutic target
among CAD patients, factors such as apolipoprotein B [apo B],
lipoprotein (a) [Lp(a)], homocysteine [Hcy], oxidative stress
etc. have also been identified as contributory factors for CAD
and have recently emerged as secondary targets of therapy.2e4
Apo B represents the circulating LDL particle number, and it
has been recognized that CAD risk is more directly related to
the number than to the cholesterol content of lipoproteins.5
Lp(a) is a LDL like particle to which a glycoprotein, apolipo-
protein(a) is covalently linked and it has higher pro-
atherogenic, pro-thrombotic potential compared with LDL.6
Elevated Hcy concentration induces oxidative stress and
damages endothelium and is considered another important
CAD risk factor.7 Oxidative stress contributes to the initiation
and exacerbation of several chronic diseases including
atherosclerosis. Elevated oxidative stress has been reported
among CAD patients in earlier studies.8 Previous in-
vestigations have shown that statins can markedly reduce
circulating apo B concentrations as well as oxidative stress.9,10
However, the effect of statins on Lp(a) and Hcy has not been
fully established.11,12
Novel risk factors and level of oxidative stress among CAD
patients of Kerala on statin therapy is not thoroughly investi-
gated. A community-based study in Kerala has shown that this
population has high prevalence of conventional risk factors for
non-communicable diseases.13 A recent study reported higher
oxidative stress among CAD subjects of this population,14 still
there is paucity of data in this direction. Hence this observa-
tional, cross sectional study was undertaken to find out if CAD
patients on statins (a class of drugs with known pleiotropic
effects) had lipid profile, apo B, Lp(a), Hcy and the degree of
oxidative stress comparable to healthy controls.2. Materials and methods
This study was conducted for a period of 16 months at a ter-
tiary care university hospital in Kerala in accordance with the
Declaration of Helsinki. The protocol for the study was
approved by the Institutional Ethics Committee, and informed
consent was obtained from all the participating subjects.
2.1. Subjects
Men aged 35e70 years, who presented to Cardiology, Endo-
crinology and Comprehensive Health Care out-patientdepartments [OPD] of the hospital for routine health check-
up, satisfying the inclusion criteria and willing to participate
in the study, were recruited.We screened 477 patients in these
OPDs and 315 were recruited in the following groups. 84 sub-
jects with normal blood glucose level, normal blood pressure,
without thyroid abnormalities, without prior history of angina
or myocardial infarction, a normal 12 lead ECG and absence of
inducible ischemia on stress test were included in group 1
(control group). 151 subjects with previously documented
myocardial infarction or inducible ischemia on stress test or
angiographically proven CAD and under statin therapy were
included in group 2. Group 3 included 80 patients with previ-
ously diagnosed type 2 diabetes mellitus, but without CAD,
thyroid or renal complications. Type 2 diabetes was diagnosed
based on WHO diagnostic criteria for diabetes [fasting blood
glucose levels >126 mg/dL].15 Subjects of groups 1 and 3 were
not on statins previously. Subjects with positive history of
anti-hypertensive medications at the time of recruitment
were considered to be hypertensives. A current tobacco user is
defined in this study as someone smoking cigarettes/beedis or
using smokeless tobaccowithin past 3months of recruitment.
The subjects furnished details regarding their diet and life
style habits in a dietary questionnaire provided during their
recruitment. Details regarding medication of the enrolled
subjects were procured from the patient file.
2.2. Laboratory analysis
2 ml of fasting blood in EDTA and 2ml without anticoagulants
was collected from each subject. The samples were centri-
fuged immediately and serum/plasma was separated.
2.2.1. Oxidative stress parameters
Parameters analyzed to evaluate oxidative stress include
reduced glutathione [GSH], glutathione peroxidase [GPx], su-
peroxide dismutase [SOD], ascorbic acid, malondialdehyde
[MDA] and oxidized LDL [oxLDL]. Erythrocytes were washed
thrice with ice-cold physiological saline, lysedwith de-ionized
water and used for estimation of GSH, GPx andMDA. GSHwas
estimated using the method of Beutler et al.16 GPx was
assayed according to Paglia and Valentine17 and as modified
by Lawrence and Burk.18 MDAwas estimated by themethod of
Jain et al.19
SOD was assayed in serum based on the method of Mar-
klund and Marklund20 and as modified by Nandi and Chat-
terjee.21 Ascorbic acid was estimated in plasma by
dinitrophenyl hydrazine assay.22 OxLDL was estimated in
plasma using Mercodia Oxidized LDL ELISA kit (Mercodia,
Sweden) based on direct sandwich ELISA technique.
2.2.2. Novel CAD risk factors
Apo B was analyzed in serum by immunoturbidimetry using
kits fromDaiichi Chemical Co., Japan. Lp(a) was determined in
serum by ELISA using ELITEST-Lp(a) kit from Hyphen Biomed,
France. Hcy concentrations were assayed in plasma samples
by ELISA using kits from Bio-Rad, USA.
2.2.3. Lipid parameters
Lipid parameters assayed included total cholesterol [TC], tri-
glycerides [TG], HDL cholesterol [HDL-C], and LDL-C, which
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auto-analyzer.
2.3. Statistical analysis
Categorical variables were represented as numbers and/or
percentages. All the other parameters were represented as
mean value and standard deviation. ANOVA was used to
compare mean values of the parameters between different
groups and a p value <0.05 was considered to be statistically
significant. If test of homogeneity of variances was significant,
post hoc analysis was done by GameseHowell test. If test of
homogeneity of varianceswas not significant, post hoc analysis
was carried out by Tukey's test. A p value<0.05was considered
statistically significant in post hoc analysis also.
Pearson's correlation analysis was performed to analyze
the degree of correlation between different parameters in
each group. Further, the groups were considered as a single
sample and after adjusting for age, multivariate linear
regression was performed to identify independent predictors
of CAD in this population. Statistical analysis of datawas done
using IBM SPSS software, version 21.0.3. Results
The number of current tobacco users was 13, 17 and 11
respectively among groups 1, 2, and 3. Subjects with hyper-
tensionwere 91 among group 2 and 33 among group 3 subjects.
Among group 2 patients, 78 subjects were diabetic. All the CAD
subjects were on statin therapy and the diabetic subjects were
on oral hypoglycemic agents or insulin therapy. Patients with
hypertension in groups 2 and 3 were on anti-hypertensive
drugs. The clinical profile of the subjects is given in Table 1.
3.1. Oxidative stress parameters
Results of analysis of parameters to measure oxidative stress
are given in Table 2. GSH, GPx, ascorbic acid, MDA (all
p ¼ 0.000) and oxLDL (p ¼ 0.001) had significant p values,
whereas SOD did not have a significant p value (p ¼ 0.664)
between the groups upon preliminary data analysis. On post
hoc analysis, it was found that controls had significantly
higher GSH compared to both CAD group and diabetics
(p¼ 0.000 for both). GPx was lower for CAD group compared toTable 1 e Clinical characteristics of subjects.
Group 1
n ¼ 84
Group 2
n ¼ 151
Group 3
n ¼ 80
Variables
Mean age (years) 50.1 56.7 52.4
Smokers (n) 13 (15%) 17 (11%) 11 (13%)
Hypertensives (n) e (0%) 91 (60%) 33 (41%)
Diabetics (n) e (0%) 78 (51%) 80 (100%)
FBS in mg/dL (Mean ± SD) 97 ± 13 116 ± 27 131 ± 21
FBS: fasting blood sugar, mg/dL: milligram/deciliter, SD: standard
deviation.controls and diabetics (p ¼ 0.000 and 0.001 respectively). GPx
was significantly lower for diabetic patients also compared to
controls (p ¼ 0.000). Ascorbic acid was lower among CAD
group compared to controls and diabetics (p ¼ 0.000 for both).
MDA was higher among CAD subjects compared to controls
and diabetics (p ¼ 0.000 for both). CAD subjects had signifi-
cantly higher oxLDL levels also compared to controls and di-
abetics (p ¼ 0.008 and 0.007 respectively).
No correlation was observed between the oxidative stress
parameters, nor between these and lipid parameters or novel
risk factors upon analysis. Upon regression analysis, GPx
(B¼0.027, p¼ 0.000), ascorbic acid (B¼0.043, p¼ 0.000), and
MDA (B ¼ 0.143, p ¼ 0.000) were found to be major predictors
for CAD.
3.2. Novel CAD risk factors
The results of biochemical analysis of apo B, Lp(a) and Hcy are
given in Table 3. Though apo Bwas higher among controls and
diabetics compared to CAD group, the p value was not sig-
nificant between the groups (p ¼ 0.21). Mean Lp(a) concen-
trations were not significantly different between the groups
(p ¼ 0.094). Mean Hcy values of the three groups had signifi-
cant p value (p ¼ 0.007) on preliminary analysis of data and
post hoc analysis showed that it was significantly higher for
CAD subjects compared to controls and diabetics (p ¼ 0.008
and 0.03 respectively), while it did not show any significant
difference between control and diabetic groups (p ¼ 0.837).
Apo B had moderate positive correlation with TC and LDL-
C among controls (r ¼ 0.414 and 0.437 respectively) as well as
CAD subjects (0.315 and 0.441 respectively), whereas no such
correlation was observed among diabetic subjects. Novel risk
factors were not found to be major predictors for CAD on
regression analysis.
3.3. Lipid parameters
The results of biochemical analysis of lipid parameters are
given in Table 3. Upon preliminary analysis it was found that
TC, TG, HDL-C and LDL-C had significant p values (p ¼ 0.000).
Post hoc analysis showed that TC was significantly higher for
controls and diabetics compared to CAD subjects (p¼ 0.000 for
both). Control group had elevated TC levels compared to di-
abetics also (p¼ 0.001). TGwas significantly higher for controls
compared to CAD subjects (p ¼ 0.001), whereas it was signifi-
cantly higher for diabetic subjects compared to CAD patients
(p ¼ 0.000) as well as controls (p ¼ 0.05). HDL-C showed sig-
nificant reduction among CAD subjects and diabetics
compared to controls (p ¼ 0.000 and 0.025 respectively), but
was not found to be significantly different between CAD and
diabetic patients (p ¼ 0.252). Mean LDL-C was found to be
significantly lowered among CAD subjects compared to sub-
jects of groups 1 and 3 (p ¼ 0.000 for both).
TC was positively correlated with LDL-C among group 1, 2
and 3 (r ¼ 0.885, 0.660 and 0.734 respectively). TG had weak
positive correlation with TC and LDL-C (r ¼ 0.387 and 0.304
respectively) and a weak negative correlation with HDL-C
(r ¼ 0.334). Among lipid parameters, TG (B ¼ 0.001,
p ¼ 0.002) and HDL-C (B ¼ 0.006, p ¼ 0.003) were found to be
major predictors for CAD upon regression analysis.
Table 2 e Results of analyses of oxidative stress parameters.
Parameters
(Mean ± SD)
Group 1 Group 2 Group 3 p Value and CI
(groups 1 & 2)
p Value and CI
(groups 1 & 3)
p Value and CI
(groups 2 & 3)
GSH (nmoles/g Hb) 7 ± 0.7 5.3 ± 0.9 5.3 ± 0.8 0.000 (1.44 to 2.03) 0.000 (1.35 to 2.02) 0.926 (0.33 to 0.24)
GPx (IU/g Hb) 18.6 ± 6.3 14.7 ± 5.9 15.9 ± 6 0.000 (3.13 to 4.82) 0.000 (1.74 to 3.68) 0.001 (2.11 to 0.43)
SOD (U/mL serum) 5 ± 1 4.9 ± 0.9 4.8 ± 1.1 0.703 (0.22 to 0.46) 0.701 (0.26 to 0.53) 0.991 (0.33 to 0.36)
Ascorbic acid (mg/L) 10.7 ± 2.4 8.8 ± 1.8 10.1 ± 2.3 0.000 (1.37 to 2.66) 0.072 (0.05 to 1.58) 0.000 (1.96 to 0.55)
MDA (nmoles/g Hb) 14.1 ± 2.1 17.2 ± 1 14.5 ± 0.6 0.000 (3.71 to 2.55) 0.303 (0.92 to 0.21) 0.000 (2.53 to 3.02)
oxLDL (U/L) 64 ± 24.5 76.5 ± 30.2 63.3 ± 26.3 0.008 (22.37 to 2.69) 0.837 (11.19 to 12.54) 0.007 (3.09 to 23.33)
SD: standard deviation, CI: Confidence Interval for mean difference, nmoles/g Hb: nanomoles per gramhemoglobin, IU/g Hb: international units
per gram hemoglobin, U/mL: units per milliliter, mg/L: milligram/liter, U/L: units per liter.
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The detrimental effects of higher oxidative stress on athero-
sclerosis include endothelial dysfunction, lipid peroxidation,
activation of several inflammatory pathways etc.23 It has been
demonstrated earlier that higher oxidative stress is common
among subjects with CAD.24 Several clinical studies suggest
that statins can reduce oxidative stress among CAD pa-
tients.10,25 But it was seen in our study that subjects under
statin therapy had lower antioxidant status as indicated by
low GSH, GPx and ascorbic acid compared to non-statin
groups, viz. diabetics as well as healthy controls. High rate
of lipid peroxidation and oxidation of LDL was also noted
among our CAD patients. This is incongruous with studies
that show that oxidative stress among CAD subjects was
reduced and was comparable to healthy individuals after
undergoing statin therapy.26 But there are few studies avail-
able that have shown that CAD subjects have higher oxidative
stress compared to healthy controls even while being clini-
cally stable and under statin therapy.27 The level of oxidative
stress among diabetic subjects was lower than those in CAD
group, but was higher compared to healthy controls. It has
been proven earlier that higher oxidative stress is prevalent
among diabetes patients28 and plays a critical role in the
development of both microvascular and cardiovascular com-
plications of diabetes.29
Studies have shown that statins can markedly reduce
circulating apo B levels, thereby reducing their CAD risk.30 But
in our study the apo B levels of CAD patients under statin
therapy was not significantly lower compared to non-statin
groups. The results of The MERCURY II trial show that to
attain clinically relevant reduction in apo B levels (<90mg/dL),Table 3 e Results of analyses of lipid parameters and novel CA
Parameters (Mean ± SD) Group 1 Group 2 Group 3
Total cholesterol (mg/dL) 208.7 ± 40 147.7 ± 32.3 182.5 ± 49.6 0
Triglycerides (mg/dL) 138.7 ± 49.8 114.6 ± 46.3 156 ± 46.1 0
HDL-cholesterol (mg/dL) 47.5 ± 10.6 39.5 ± 14.7 42.3 ± 10 0
LDL-cholesterol (mg/dL) 129.8 ± 32.9 91.7 ± 27.4 121.7 ± 45.1 0
Apo B (mg/dL) 96.3 ± 17.2 91.2 ± 19.9 93.1 ± 18.8 0
Lp(a) (mg/dL) 18.8 ± 7.6 21.8 ± 9.4 21.1 ± 8.4 0
Hcy (mmoles/L) 13.6 ± 5.6 16.6 ± 8.6 14.1 ± 5.1 0
SD: standard deviation, CI: Confidence Interval for mean difference, mmothe LDL-C concentration should be reduced below 70 mg/dL
among hypertriglyceridemics and below 80 mg/dL among
non-hypertriglyceridemics.31 The elevated apo B concentra-
tions among CAD subjects of our study could be because their
LDL-C level was higher than the measure required for a sig-
nificant apo B reduction. Since apo B levels were correlated
with LDL-C levels in our study subjects, further reduction in
LDL-C by aggressive statin therapy may concurrently reduce
their apo B levels also.
Hitherto, the studies on the effect of statins on Lp(a) are
sparse and the data generated from these are disparate.32,33
The results from the present study show that Lp(a) concen-
tration did not differ significantly between CAD patients on
statin therapy compared to both non-statin groups. An earlier
study among CAD patients of Kerala has shown that their
Lp(a) level was not considerably high when compared to
healthy controls.34 Most of the available literature show that
statin therapy has no detectable or clinically relevant effect on
Hcy levels.35,36 Hcy concentrations of the CAD patients of this
study was significantly elevated than diabetics and controls
and this level is higher than that reported by a study in related
population.37
The CAD patients of this study had healthier lipid profile,
as expected, in terms of TC, TG and LDL-C level compared to
the subjects of the other two groups. Elevated LDL-C noted
among controls and diabetics of this study was comparable to
earlier reports from this population.38 The mean HDL-C level
among the CAD subjects of this study was low, and is
consistent with results from studies on other Indian CAD
populations.39,40 An earlier study has shown that HDL-C is low
even among general population of this region.13 It is note-
worthy that dyslipidemia (TG > 150 mg/dL and HDL-C
<40 mg/dL), an established risk aggravator for CAD,41 wasD risk factors.
p Value and CI
(groups 1 & 2)
p Value and CI
(groups 1 & 3)
p Value and CI
(groups 2 & 3)
.000 (48.9 to 73.1) 0.001 (9.6 to 42.9) 0.000 (20.3 to 49.3)
.001 (8.9 to 39.3) 0.05 (34.8 to 0.99) 0.000 (57 to 25.9)
.000 (3.94 to 12.1) 0.025 (0.53 to 9.86) 0.252 (6.96 to 1.35)
.000 (28.03 to 48.1) 0.399 (6.69 to 22.87) 0.000 (43.24 to 16.71)
.185 (1.69 to 11.68) 0.589 (4.49 to 10.91) 0.802 (8.44 to 4.87)
.077 (6.27 to 0.25) 0.328 (6.03 to 1.48) 0.852 (2.48 to 3.96)
.008 (5.33 to 0.65) 0.837 (2.67 to 1.63) 0.03 (0.19 to 4.75)
les/L: micromoles/liter, mg/dL: milligram/deciliter.
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compared to controls (9%) or CAD patients (16%).5. Conclusions
In spite of therapeutical intervention by statins, a drug with
proven antioxidant capabilities, CAD subjects in this study
had higher oxidative stress. Lipid profile levels of CAD patients
were healthier compared to diabetics or controls. Novel risk
factors such as apo B, Lp(a) etc. were not considerably
different between these three groups.6. Limitations of the study
The type/dosage/duration of statin treatment was not
considered while recruiting the subjects. The parameters
considered were not measured before statin therapy among
CAD subjects. Differences in micronutrient intake in the form
of vitamin supplements and dietary differences (both inter-
group and intra-group) must also have influenced the results.Financial support
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